IP Library Granted Patent US 12,318,404
Granted Patent B2
US 12,318,404 · App. 15/409,379 · Granted Jun 3, 2025

Hypochlorite formulations for wound healing

Inventors: Andrew Hoover (Pleasant Grove, UT); Kurt Richards (Herriman, UT)
Assignee: Reoxcyn LLC
A61K33/20A61K8/19A61K8/24A61K8/25A61K8/891A61K9/0014A61K9/08A61K45/06A61K47/02A61K47/24A61K47/34A61L26/0004A61Q19/08C25B1/26A61K2800/81
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,318,404
App. No.
15/409,379
Granted
Jun 3, 2025
Kind
B2
Abstract

A formulation is disclosed for use in wound healing. The formulation may include hypochlorous acid, a silicone polymer or blend thereof, sodium phosphate, hydrochloric acid, and sodium magnesium silicate. Methods of using and making the wound healing formulation are also disclosed.

Claims (41)

1. A method of treating a burn in a subject afflicted with a burn, the method comprising:

applying to a burn a therapeutically effective amount of a formulation consisting of:

an electrolyzed saline solution having a salt concentration between 0.1% and 1% by weight, hypochlorite present in an amount of between 0.6 and 1% w/v, hypochlorous acid, dissolved oxygen, chlorine, hydrogen gas, hydrogen peroxide, hydrogen ions, hypochloride, ozone, activated hydrogen ions, chloride ions, hydroxides, singlet oxygen, *OCl, *HO − , and superoxides of *O 2 — and HO 2 ;

a buffer, wherein the formulation has a pH ranging from 6.7 to 7.5;

sodium magnesium silicate; and

dimethicone,

wherein the formulation has an osmolality measurement ranging from about 22 mOsm/kg to about 54 mOsm/kg; and

allowing the formulation to absorb into the burn, thereby treating the burn.

2. The method of claim 1 , wherein applying comprises topically administering the formulation to the burn.

3. The method of claim 1 , wherein the formulation is an ointment, cream, spray, gel, lotion, or solution.

4. The method of claim 1 , wherein the formulation is applied to the burn at least once daily.

5. The method of claim 1 , wherein the formulation is applied to the burn three times a day.

6. The method of claim 1 , wherein a rate of healing of the burn is accelerated as compared to a rate of healing of a non-treated burn.

7. The method of claim 1 , wherein the therapeutically effective amount is an amount effective to accelerate burn healing, promote burn closure, or cause burn regression.

8. The method of claim 1 , wherein the applying the formulation reduces, attenuates, or prevents bacterial growth or infection in the burn.

9. The method of claim 1 , wherein the buffer is in an amount of about 0.2% w/v, wherein the sodium magnesium silicate is in an amount of about 3.25% w/v, and wherein the dimethicone is in an amount of about 5.0% w/v.

10. The method of claim 1 , wherein the buffer is an acetate, an ascorbate, a carbonate, a phosphate, a citrate, or an organic based buffer.

11. The method of claim 1 , wherein the buffer comprises sodium phosphate monobasic.

12. A system for healing a burn, comprising:

a wound dressing material having a therapeutically effective amount of a formulation applied thereto, wherein the wound is a burn,

wherein the formulation consists of:

an electrolyzed saline solution having a salt concentration between 0.1% and 1% by weight, hypochlorite present in an amount of between 0.6 and 1% w/v, hypochlorous acid, dissolved oxygen, chlorine, hydrogen gas, hydrogen peroxide, hydrogen ions, hypochloride, ozone, activated hydrogen ions, chloride ions, hydroxides, singlet oxygen, *OCl, *HO − , and superoxides of *O 2 — and HO 2 ;

a buffer present in an amount of about 0.2% w/v, wherein the formulation has a pH ranging from 6.7 to 7.5;

sodium magnesium silicate; and

dimethicone,

wherein the formulation has an osmolality measurement ranging from about 22 mOsm/kg to about 54 mOsm/kg.

13. The system of claim 12 , wherein the wound dressing material is a bandage, a wipe, a gauze, a sponge, a mesh, or an absorbent wound dressing material.

14. The system of claim 12 , wherein the hypochlorite is in an amount of about 0.6% w/v, wherein the buffer is in an amount of about 0.2% w/v, wherein the sodium magnesium silicate is in an amount of about 3.25% w/v, and wherein the dimethicone is in an amount of about 5.0% w/v.

15. The method of claim 1 , wherein the burn is a thermal burn, a radiation burn, or a chemical burn.

16. The method of claim 1 , wherein the formulation is applied to a wound dressing material prior to application to the burn.

17. A method of treating a burn on an individual, the method comprising:

topically applying to the burn a therapeutically effective amount of a formulation consisting of:

an electrolyzed saline solution having a salt concentration between 0.1% and 1% by weight, hypochlorite present in an amount of about 0.6% w/v, hypochlorous acid, dissolved oxygen, chlorine, hydrogen gas, hydrogen peroxide, hydrogen ions, hypochloride, ozone, activated hydrogen ions, chloride ions, hydroxides, singlet oxygen, *OCl, *HO − , and superoxides of *O 2 — and HO 2 ;

sodium phosphate present in an amount of about 0.2% w/v, wherein the formulation has a pH ranging from 6.7 to 7.5;

sodium magnesium silicate present in an amount of about 3.25% w/v; and

dimethicone present in an amount of about 5% w/v,

wherein the formulation has an osmolality measurement ranging from about 22 mOsm/kg to about 54 mOsm/kg; and

allowing the formulation to absorb into the burn, thereby treating the burn.

18. The method of claim 17 , wherein applying the formulation to the burn accelerates healing of the burn.

19. The method of claim 1 , wherein the therapeutically effective amount of the formulation is in a range from about 0.1 g to about 1 g.

20. The method of claim 1 , wherein the therapeutically effective amount of the formulation is in an amount of about 0.4 g.

Assignments (3)
CHANGE OF NAME Recorded Jul 24, 2018
From: REOXCYN INNOVATION GROUP, LLC
To: REOXCYN, LLC.
Reel/Frame 046620/0800 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 31, 2018
From: REOXCYN DISCOVERIES GROUP, INC.
To: REOXCYN INNOVATION GROUP, LLC
Reel/Frame 044783/0981 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 22, 2017
From: HOOVER, ANDREW; RICHARDS, KURT
To: REOXCYN DISCOVERIES GROUP, INC.
Reel/Frame 041683/0256 →
Continuity (2)
Provisional Application 62280613 · Jan 19, 2016
Related Publication 20170202877A1 · Jul 20, 2017
References Cited (115)
US 1200165A · Burgess · 1916 [cited by applicant]
US 4236992A · Themy · 1980 [cited by applicant]
US 4316787A · Themy · 1982 [cited by applicant]
US 4671955A · Palinczar · 1987 [cited by applicant]
US 4810344A · Okazaki · 1989 [cited by applicant]
US 4956184A · Kross · 1990 [cited by applicant]
US 5334383A · Morrow · 1994 [cited by applicant]
US 5507932A · Robinson · 1996 [cited by applicant]
US 5674537A · Morrow · 1997 [cited by applicant]
US 6007686A · Welch · 1999 [cited by applicant]
US 6042618A · Berndt · 2000 [cited by examiner]
US 6114398A · Ratcliff · 2000 [cited by applicant]
US 6117285A · Welch · 2000 [cited by applicant]
US 6333054B1 · Rogozinski · 2001 [cited by applicant]
US 7108997B2 · Kettle · 2006 [cited by applicant]
US 7276255B2 · Selkon · 2007 [cited by examiner]
US 7622434B2 · Rogozinski · 2009 [cited by examiner]
US 7691249B2 · Daly · 2010 [cited by applicant]
US 8062501B2 · Omasa · 2011 [cited by applicant]
US 8323252B2 · Alimi · 2012 [cited by applicant]
US 8518382B2 · Speronello et al. · 2013 [cited by applicant]
US 8673297B2 · Speronello et al. · 2014 [cited by applicant]
US 8784900B2 · Northey · 2014 [cited by applicant]
US 9072793B2 · Eckert et al. · 2015 [cited by applicant]
US 9175141B2 · Wray et al. · 2015 [cited by applicant]
US 9474768B1 · Richards · 2016 [cited by applicant]
US 9833406B1 · Richards · 2017 [cited by applicant]
US 20020114849A1 · Camper et al. · 2002 [cited by applicant]
US 20040137078A1 · Najafi · 2004 [cited by examiner]
US 20050089537A1 · Birnholz · 2005 [cited by applicant]
US 20050196462A1 · Alimi · 2005 [cited by applicant]
US 20060051387A1 · Green · 2006 [cited by examiner]
US 20060241546A1 · Alimi · 2006 [cited by applicant]
US 20070021213A1 · Foe · 2007 [cited by applicant]
US 20070172412A1 · Hratko et al. · 2007 [cited by applicant]
US 20070243264A1 · Garabedian · 2007 [cited by examiner]
US 20070281008A1 · Lin et al. · 2007 [cited by applicant]
US 20080003171A1 · Smith et al. · 2008 [cited by applicant]
US 20080008621A1 · Masahiro et al. · 2008 [cited by applicant]
US 20080110803A1 · Veltri · 2008 [cited by examiner]
US 20080160612A1 · Selkon · 2008 [cited by applicant]
US 20080206371A1 · Fontaine · 2008 [cited by examiner]
US 20090028811A1 · Potter · 2009 [cited by applicant]
US 20090068122A1 · Shira et al. · 2009 [cited by applicant]
US 20090148342A1 · Bromberg et al. · 2009 [cited by applicant]
US 20090169646A1 · Bosch et al. · 2009 [cited by applicant]
US 20090258083A1 · Calderon · 2009 [cited by applicant]
US 20100012132A1 · Harrison et al. · 2010 [cited by applicant]
US 20100078331A1 · Scherson · 2010 [cited by applicant]
US 20100196454A1 · Keller · 2010 [cited by examiner]
US 20100197748A1 · Schwarz et al. · 2010 [cited by applicant]
US 20100274176A1 · Baumgart · 2010 [cited by examiner]
US 20100285151A1 · Goldan · 2010 [cited by applicant]
US 20100330203A1 · Kross · 2010 [cited by examiner]
US 20110052506A1 · Abel et al. · 2011 [cited by applicant]
US 20110121110A1 · Field · 2011 [cited by applicant]
US 20120046556A1 · Block · 2012 [cited by applicant]
US 20120148516A1 · Abel · 2012 [cited by examiner]
US 20120164235A1 · Northey · 2012 [cited by examiner]
US 20120237616A1 · Panicheva · 2012 [cited by examiner]
US 20130095138A1 · Norton · 2013 [cited by examiner]
US 20130150451A1 · Salamone · 2013 [cited by examiner]
US 20130164228A1 · Stanislav et al. · 2013 [cited by applicant]
US 20130168260A1 · Scherson et al. · 2013 [cited by applicant]
US 20130236563A1 · Samuelson · 2013 [cited by applicant]
US 20130243883A1 · Norton · 2013 [cited by examiner]
US 20140044800A1 · Robinson · 2014 [cited by applicant]
US 20140328946A1 · Northey · 2014 [cited by applicant]
US 20140369953A1 · Purschwitz · 2014 [cited by applicant]
US 20150017257A1 · Megumi et al. · 2015 [cited by applicant]
US 20150093451A1 · Neiman · 2015 [cited by applicant]
US 20150099010A1 · Hoover · 2015 [cited by applicant]
US 20150118180A1 · Hoover · 2015 [cited by applicant]
US 20150125543A1 · Croke et al. · 2015 [cited by applicant]
US 20150246131A1 · Romanoschi et al. · 2015 [cited by applicant]
US 20150250704A1 · Romanoschi et al. · 2015 [cited by applicant]
US 20160198720A1 · Yoshida · 2016 [cited by examiner]
CN 102167997 · 2013 [cited by applicant]
EP 0335584 · 1989 [cited by applicant]
EP 1886664 · 2008 [cited by applicant]
MX 2016013933A · 2017 [cited by examiner]
WO WO9934773 · 1999 [cited by applicant]
WO WO2006102680A2 · 2006 [cited by examiner]
WO WO2010004699 · 2010 [cited by applicant]
WO WO2015002932 · 2015 [cited by applicant]
WO WO2016100543 · 2016 [cited by applicant]
WO WO2017127452 · 2017 [cited by applicant]
Ahmed et al.; “Effectiveness of 0.025% Dakin's Solution Versus 1% Silver Sulphadiazine for Treatment of Partial Thickness Burns,” Ann. Pak. Inst. Med. Sci. 2011; 7(3): 127-132. [cited by examiner]
Dow Corning® presentation titled “What are Silicones?”, Retrieved from http://www.doorirng.com/data/Silicone%20Chemistry.pdf on Jun. 4, 2019 (pp. 1-29). (Year: 2019). [cited by examiner]
Liu, et al., Effects of Exogenous Silicon on the Activities of Antioxidant Enzymes and Lipid Peroxidation in Chilling-Stressed Cucumber Leaves, JIA, 2009, vol. 8(9), p. 1075-1086. (Year: 2009). [cited by examiner]
Balakhnina, T. et al., Effects of silicon on plant resistance to environmental stresses: review, Int. Agrophys., 2013/27,225-232. (Year: 2013). [cited by examiner]
O'Lenick, Anthony Jr., Silicone Spectator, 1999, pp. 1-23. (Year: 1999). [cited by examiner]
Bleasdale et al.; “The Use of Silicone Adhesives for Scar Reduction,” 2015, Wound Healing Society, Advances in Wound Care, vol. 4, No. 7, pp. 422-430. (Year: 2015). [cited by examiner]
Van der wal et al.; “Topical Silicone Gel versus Placebo in Promoting the Maturation of Burn Scars: A Randomized Controlled Trial,” 2010, American Society of Plastic Surgeons; Plastic and Reconstructive Surgery, vol. 12… [cited by examiner]
Rutala et al.; New Disinfection and Sterilization Methods, 2001, Emerging Infectious Diseases, vol. 7, No. 2, pp. 348-353. (Year: 2001). [cited by examiner]
Bunyan, John; “The Treatment of Burns by Hypochlorite Solution,” 1983, Journal of Tropical Pediatrics, vol. 29, No. 2, pp. 93-94. (Year: 1983). [cited by examiner]
Merriam-Webster's Collegiate Dictionary, 11th ed., 2004, entry for “impregnate” p. 625. (Year: 2004). [cited by examiner]
Ansel et al.; “Pharmaceutical Dosage Forms and Drug Delivery Systems, 7th ed.,” Lippincott, Williams and Wilkins, pp. 414-417. (Year: 1999). [cited by examiner]
Sinko, Patrick J.; “Martin's Physical Pharmacy and Pharmaceutical Sciences,” Lippincott, Williams and Wilkins, pp. 119-141 and 143-160. (Year: 2006). [cited by examiner]
Kerckhove et al.; “Silicones in the rehabilitation of burns: a review and overview,” 2001, Elsevier; Burns, vol. 27, pp. 205-214, (Year: 2001). [cited by examiner]
International Search Report and Written Opinion for PCT/US2017/013979, mailed May 2, 2017. [cited by applicant]
Alnashef et al. Electrochemical Generation of Superoxide In Room-Temperature Ionic Liquids. Electrochemical and Solid State Letters, 4 (11) D16-D18 (2001). [cited by applicant]
AlNashef et al. Superoxide Electrochemistry in an Ionic Liquid. Ind. Eng. Chem. Res. 2002, 41, 4475-4478. [cited by applicant]
Bielski et al. Reactivity of H02/02—Radicals in Aqueous Solution. J. Phys. Chem. Ref. Data, vol. 14, No. 4 1985. [cited by applicant]
Chen, “Novel technologies for the prevention and treatment of dental caries: a patent survey”, Expert Opin Ther Pat. May 2010; 20(5): 681-694. [cited by applicant]
Hayann et al. Generation and stability of superoxide ion in tris(pentafluoroethyl) trifluorophosphate anion-based ionic liquids. J Fluorine Chem. vol. 142, 2012, 83-89. [cited by applicant]
Hayyan et al. Long term stability of superoxide ion in piperidinium, pyrrolidinium and phosphonium cations-based ionic liquids and its utilization in the destruction of chlorobenzenes. Journal of Electroanalytical Chemi… [cited by applicant]
Kahn et al. Spin Traps: In Vitro Toxicity and Stability of Radical Adducts. Free Radical Biology & Medicine, vol. 34, No. 11, pp. 1473-1481, 2003. [cited by applicant]
Kariduraganavar et al. Ion-exchange membranes: preparative methods for electrodialysis and fuel cell applications. Desalination 197 (2006) 225-246. [cited by applicant]
Konaka et al. Irradiation of Titanium Dioxide Generates Both Singlet Oxygen and Superoxide Anion. Free Radical Biology & Medicine, vol. 27, Nos. 3/4, pp. 294-300, 1999. [cited by applicant]
Prasanth, “Antimicrobial Efficacy of Different Toothpastes and Mouthrinses: An In Vitro Study”, Dent Res J (Isfahan), 2011 Spring, 8(2); 85-94. [cited by applicant]
Zoulias et al. A Review on Water Electrolysis last modified Jan. 20, 2006 15:24. [cited by applicant]
“High purity, activated HCIO Perfect Perio”, http://amanodental.com/english/PerfectPerio-how-to-use.pdf, Nov. 2010. [cited by applicant]
PCT Search Report and Written Opinion for PCT Application No. PCT/US2016/056760, filed Oct. 13, 2016, dated Jan. 16, 2017. [cited by applicant]
PCT International Search Report in PCT/US2017/051283, mailed Nov. 29, 2017. [cited by applicant]